Miller V - Search Results

1

Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, Majumder M, Zhong J, Huml RA, Miller V. Kidwell KM, et al. Among authors: miller v. Orphanet J Rare Dis. 2022 May 7;17(1):186. doi: 10.1186/s13023-022-02342-5. Orphanet J Rare Dis. 2022. PMID: 35526036 Free PMC article. Review.

2

The Use of External Controls in FDA Regulatory Decision Making.

Jahanshahi M, Gregg K, Davis G, Ndu A, Miller V, Vockley J, Ollivier C, Franolic T, Sakai S. Jahanshahi M, et al. Among authors: miller v. Ther Innov Regul Sci. 2021 Sep;55(5):1019-1035. doi: 10.1007/s43441-021-00302-y. Epub 2021 May 20. Ther Innov Regul Sci. 2021. PMID: 34014439 Free PMC article. Review.

3

The forum for collaborative HIV research: a model for an integrated and inclusive approach to clinical research and drug development.

Miller V. Miller V. Clin Pharmacol Ther. 2009 Sep;86(3):332-5. doi: 10.1038/clpt.2009.140. Epub 2009 Jul 29. Clin Pharmacol Ther. 2009. PMID: 19641490 Review. No abstract available.

4

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.

Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Hutchison C, et al. Among authors: miller v. Clin Pharmacol Ther. 2014 Aug;96(2):162-5. doi: 10.1038/clpt.2014.113. Epub 2014 May 22. Clin Pharmacol Ther. 2014. PMID: 24853733 Review.

5

Treatment interruptions in the salvage setting: what have we learned?

Miller V. Miller V. Res Initiat Treat Action. 2003 Fall;9(2):17-9. Res Initiat Treat Action. 2003. PMID: 14989202 No abstract available.

6

Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition.

Miller V, Grant RM. Miller V, et al. Clin Pharmacol Ther. 2014 Aug;96(2):153-5. doi: 10.1038/clpt.2014.114. Clin Pharmacol Ther. 2014. PMID: 25056397 Review.

7

Improving evidence developed from population-level experience with targeted agents.

McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL. McClellan MB, et al. Among authors: miller v. Clin Pharmacol Ther. 2015 May;97(5):478-87. doi: 10.1002/cpt.90. Epub 2015 Apr 3. Clin Pharmacol Ther. 2015. PMID: 25676878 Review.

8

Perspectives on Design Approaches for HIV Prevention Efficacy Trials.

Prudden HJ, Tatoud R, Janes H, Wallace S, Miller V, Bekker LG, Donnell D. Prudden HJ, et al. Among authors: miller v. AIDS Res Hum Retroviruses. 2024 May;40(5):301-307. doi: 10.1089/AID.2022.0150. Epub 2023 Sep 4. AIDS Res Hum Retroviruses. 2024. PMID: 37392020

9

Benefits and limitations of different study designs for long-acting antiretroviral therapy among people living with HIV with viremia.

Gandhi M, Nachega J, Miller V, Wilkin T. Gandhi M, et al. Among authors: miller v. J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26093. doi: 10.1002/jia2.26093. J Int AIDS Soc. 2023. PMID: 37439071 Free PMC article. No abstract available.

10

Perceived Readiness for Gerontological Social Work: Insights from Recent Graduates During COVID-19.

Beltran SJ, Miller VJ, Morris A. Beltran SJ, et al. Among authors: miller vj. J Gerontol Soc Work. 2024 Jun 2:1-15. doi: 10.1080/01634372.2024.2361080. Online ahead of print. J Gerontol Soc Work. 2024. PMID: 38824619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,920 results

Search Page